RxDoctor Payments DataLook up a doctor →

Melanie Thompson, MD

Internal Medicine · Atlanta, GANPI 1235272428

Payments from drug & device makers

$1,106,837in general payments, 2019–2025

Across 257 payments — averaging $4306.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$469K
  • Viiv Healthcare Company$390K
  • Cepheid$192K
  • Merck$55K
  • Pfizer$56
  • Medtronic$53
  • plus $214 from 9 others

What the payments were for

  • Food & beverage$487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,106,837 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$41,687
Medicare patients
49
Services billed
368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala74$327,245
TivicayDolutegravir Sodium70$242,717
TriumeqAbacavir/Dolutegravir/Lamivudi39$176,369
DescovyEmtricitabine/Tenofov Alafenam47$135,974
OdefseyEmtricitab/Rilpiviri/Tenof Ala24$111,217
PrezcobixDarunavir/Cobicistat17$62,707
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$50,929
JulucaDolutegravir/Rilpivirine14$49,171
SelzentryMaraviroc12$41,739
OzempicSemaglutide30$35,896
DovatoDolutegravir Sodium/Lamivudine12$35,144
Isentress HdRaltegravir Potassium15$30,166
DelstrigoDoravirine/Lamivu/Tenofov Diso11$28,889
EliquisApixaban21$12,197
Atorvastatin Calcium141$1,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$468,912$514,148134 claims
Viiv Healthcare CompanyTivicay, Triumeq, Juluca, Dovato$390,297$503,402135 claims
Johnson & JohnsonPrezcobix$15$62,70717 claims
MerckIsentress Hd, Delstrigo$54,882$59,05626 claims
PfizerSelzentry, Eliquis$56$53,93633 claims
Novo NordiskOzempic$39$35,89630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →